Evidence map›Paper›PMID 39247185›Full record

ArticleFrontiers in immunology2024

Durable response to pembrolizumab in hepatic metastasis from colonic carcinoma with Lynch syndrome: a case report.

Cheng Xue, Dongqing Zhu, Xin Wang, Lina Jiao, Yunhui Lu, Sanli Zhang, Jiayi Lv, Linlin Cui, Mengna Ruan, Dechao Xu and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cheng Xue *Kidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Dongqing Zhu *Department of Radiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Xin Wang *Department of Health Management Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Lina Jiao *Kidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Yunhui LuKidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Sanli ZhangKidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Jiayi LvKidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Linlin CuiKidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Mengna RuanKidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Dechao XuKidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Qingyang LiuDepartment of Radiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Yun FengDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuqin MeiKidney Institute, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pembrolizumab and other immunotherapies have become central in treating metastatic colon cancer, particularly effective in patients with mismatch repair deficiencies. We report a case involving a man who initially underwent radical surgery for sigmoid colon cancer on April 27, 2011, followed by hepatic tumor resection on September 21, 2017. Post-surgery, he received eight cycles of adjuvant chemotherapy with the CAPEOX regimen and was regularly monitored through CT and MRI scans. On August 24, 2022, liver metastases were detected, and he was diagnosed with Lynch syndrome (LS) due to germline mutation in the

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalColorectal Neoplasms, Hereditary NonpolyposisLiver NeoplasmsColonic NeoplasmsEpithelial Cell Adhesion MoleculeHumansMaleMiddle AgedMutS Homolog 2 ProteinTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalEPCAM protein, humanEpithelial Cell Adhesion MoleculeMSH2 protein, humanMutS Homolog 2 Proteinpembrolizumabimmune-checkpoint inhibitorsLynch syndromemetastatic colorectal cancermismatch repair deficienciestreatment related adverse event

Identifiers

PMID39247185
PMCPMC11377275

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.